Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$622M |
| 2 |
Alibaba
BABA
|
+$509M |
| 3 |
Goldman Sachs
GS
|
+$500M |
| 4 |
Microsoft
MSFT
|
+$365M |
| 5 |
Halliburton
HAL
|
+$278M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$686M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$629M |
| 3 |
Kroger
KR
|
+$617M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$545M |
| 5 |
Morgan Stanley
MS
|
+$389M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 19.67% |
| 2 | Technology | 18.06% |
| 3 | Healthcare | 16.18% |
| 4 | Communication Services | 11.92% |
| 5 | Financials | 9.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LJPC
501
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $6.13M | 0.01% |
257,709
+5,272
| +2% | +$99.3K |
|
502
BioCryst Pharmaceuticals
BCRX
$2.43B
| $5.96M | 0.01% |
1,351,330
-4,972
| -0.4% | -$19.9K |
|
503
MacroGenics
MGNX
$254M
| $5.84M | 0.01% |
195,111
-1,051
| -0.5% | -$31.3K |
|
504
Norfolk Southern
NSC
$77.1B
| $5.82M | 0.01% |
59,978
-571
| -0.9% | -$52K |
|
505
Syndax Pharmaceuticals
SNDX
$1.82B
| $5.82M | 0.01% |
383,776
-153,769
| -29% | -$2.02M |
|
|
AM
506
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $5.52M | 0.01% |
206,605
+2,758
| +1% | +$73.2K |
|
507
Artisan Partners
APAM
$2.86B
| $5.33M | 0.01% |
196,030
-381,499
| -66% | -$10.4M |
|
|
BOLD
508
DELISTED
Audentes Therapeutics, Inc
BOLD
| $5.32M | 0.01% |
+298,586
| New | +$4.53M |
|
509
CALL
Bausch Health
BHC
$1.67B
| $4.91M | 0.01% |
+200,000
| New | +$5.18M |
|
|
TRVN
510
DELISTED
Trevena, Inc.
TRVN
| $4.75M | 0.01% |
1,126
-4
| -0.4% | -$17.1K |
|
|
ISEE
511
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $4.61M | 0.01% |
+100,000
| New | +$5.64M |
|
512
WSFS Financial
WSFS
$4.14B
| $4.41M | ﹤0.01% |
120,868
+105,166
| +670% | +$3.79M |
|
513
ExxonMobil
XOM
$642B
| $4.33M | ﹤0.01% |
49,656
-1,269
| -2% | -$113K |
|
|
TCP
514
DELISTED
TC Pipelines LP
TCP
| $4.29M | ﹤0.01% |
75,224
+21,393
| +40% | +$1.16M |
|
515
Regenxbio
RGNX
$622M
| $4.09M | ﹤0.01% |
292,022
-380
| -0.1% | -$4.19K |
|
|
TRHC
516
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $3.86M | ﹤0.01% |
+269,665
| New | +$3.94M |
|
|
ENBL
517
DELISTED
ENABLE MIDSTREAM PARTNERS, LP
ENBL
| $3.8M | ﹤0.01% |
248,945
-87,031
| -26% | -$1.23M |
|
|
CACB
518
DELISTED
Cascade Bancorp
CACB
| $3.77M | ﹤0.01% |
+621,642
| New | +$3.63M |
|
|
ITCI
519
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.69M | ﹤0.01% |
+241,800
| New | +$9.78M |
|
520
State Street Utilities Select Sector SPDR ETF
XLU
$23.5B
| $3.65M | ﹤0.01% |
+148,930
| New | +$3.78M |
|
521
FB Financial Corp
FBK
$2.94B
| $3.53M | ﹤0.01% |
+175,000
| New | +$3.6M |
|
522
Warner Bros
WBD
$63.4B
| $3.47M | ﹤0.01% |
+128,773
| New | +$3.3M |
|
523
Intel
INTC
$462B
| $3.43M | ﹤0.01% |
90,980
-12,726
| -12% | -$451K |
|
524
Baxter International
BAX
$12.1B
| $3.41M | ﹤0.01% |
71,671
-2,076
| -3% | -$97.9K |
|
|
ENLK
525
DELISTED
EnLink Midstream Partners, LP
ENLK
| $3.4M | ﹤0.01% |
+192,076
| New | +$3.37M |
|
Similar funds
Jennison Associates's Q3 2016 Portfolio in Review
As of Q3 2016, Jennison Associates held 716 positions worth $92.8B, up 1.8% from $91.1B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jennison Associates withdrew a net $3.95B in Q3 2016, closing 67 positions and reducing 379 holdings. Its most notable exit was IHS INC CL-A COM STK, an estimated $131M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 20% of assets, up from 19% a quarter earlier, followed by Technology and Healthcare.
Against the trend, Jennison Associates opened a new position in FedEx worth $216M.
- Jennison Associates's largest Q3 2016 buy was FedEx: 1,233,863 shares worth $216M.
- Jennison Associates added most to Qualcomm in Q3 2016, an estimated $622M increase.
- Jennison Associates's biggest Q3 2016 reduction was Walt Disney, cutting an estimated $686M.
- Jennison Associates fully exited IHS INC CL-A COM STK in Q3 2016, selling an estimated $131M.
- Jennison Associates's ten largest holdings make up 25% of its $92.8B portfolio in Q3 2016.
- Jennison Associates opened 86 new positions and closed 67 in Q3 2016.
- Jennison Associates's portfolio value rose 1.8% quarter-over-quarter to $92.8B.
Based on Jennison Associates's 13F filing for Q3 2016, filed 1 Nov 2016.